• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Flora Growth Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    12/22/25 5:03:12 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FLGC alert in real time by email
    Flora Growth Corp.: Form 8-K - Filed by newsfilecorp.com

    false 2025-12-19 0001790169 00-0000000 Flora Growth Corp. 0001790169 2025-12-19 2025-12-19

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 19, 2025

    FLORA GROWTH CORP.
    (Exact name of registrant as specified in its charter)

    Ontario 001-40397 Not Applicable
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation) File Number) Identification No.)

    3230 W. Commercial Boulevard, Suite 180
    Fort Lauderdale, Florida, United States 33309
    (Address of principal executive offices) (ZIP Code)

    Registrant’s telephone number, including area code: (954) 842-4989

    Not Applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common Shares, no par value   FLGC   NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

    Emerging growth company ☑

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    Flora Growth Corp., a corporation organized under the laws of the Province of Ontario (the "Company") held its 2025 Special Meeting of Shareholders (the "Meeting") on December 19, 2025.

    The 2022 Plan Amendment

    At the Meeting, the Company's shareholders approved an amendment (the "2022 Plan Amendment") of the Company's 2022 Incentive Compensation Plan, as amended on June 6, 2023, August 14, 2024 and June 30, 2025 (the "2022 Plan") to (i) increase the number of common shares of the Company (the "Common Shares") issuable thereunder from 115,385 to 1,506,892 and (ii) increase the number of Incentive Stock Options (as defined in the 2022 Plan) issuable thereunder from 21,795 to 847,843.

    The 2022 Plan Amendment became effective immediately upon shareholder approval at the Meeting. A more complete summary of the terms of the 2022 Plan Amendment is set forth in "Proposal 3: Approval of Amendment to the 2022 Plan" in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 4, 2025 (the "Proxy Statement"), which description and text are incorporated herein by reference.

    The foregoing description of the terms of the 2022 Plan Amendment and the description thereof incorporated by reference from the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the 2022 Plan, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Stock Option Grants to CEO, CFO and Executive Chairman 

    Subsequent to the approval of the 2022 Plan Amendment, the independent members of the board of directors of the Company (the "Board") granted stock options (the "Stock Option Grants") pursuant to the 2022 Plan, as amended by the 2022 Plan Amendment to the Company's Chief Executive Officer, Chief Financial Officer and Executive Chairman consistent with the disclosure set forth in "Executive Compensation - Employment and Consulting Agreements, Arrangements or Plans - Daniel-Faria Employment Agreement, - Chief Financial Officer Employment Agreement and - Executive Chairman Employment Agreement" in the Definitive Proxy Statement for the Meeting.  The Form of Stock Option Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K, is incorporated herein by reference. The Stock Option Grants were issued in lieu of the stock options contemplated in Proposal No. 4 in the Proxy Statement for the Meeting. 

    Item 5.07 Submission of Matters to a Vote of Security Holders.  

    The final voting results for the proposals submitted to a vote of the Company's shareholders at the Meeting are as follows: 

    Proposal 1: Give the Board the authority, at its discretion, to file Articles of Amendment to the Company's amended and restated Articles of Incorporation to change the name of the Company to "ZeroStack Corp." or to such other name as the Board, in its sole discretion, determines to be appropriate. 

    For Against Abstentions
    307,327 53,559 1,695

    Proposal 2: Give the Board the authority, at its discretion, to file Articles of Amendment to the Company's amended and restated Articles of Incorporation to create a new class of preferred shares, issuable in series, and to provide for the rights, privileges, restrictions and conditions attaching to the Common Shares and the preferred shares, as a class. 


          Broker
    For Against Abstentions Non-Votes
    165,494 32,278 435 164,374

    Proposal 3: Approval of the 2022 Plan Amendment to the 2022 Plan, to (i) increase the number of Common Shares issuable thereunder from 115,385 to 10% of the fully diluted Common Shares as of the date the shareholders approve the 2022 Plan Amendment and (ii) increase the number of Incentive Stock Options issuable thereunder from 21,795 to the lower of (A) 2,000,000 and (B) the number of Common Shares issued and outstanding as of the date the shareholders approve the 2022 Plan Amendment. 

          Broker
    For Against Abstentions Non-Votes
    167,124 30,477 606 164,374

    Proposal 4: Approval of the grant of stock options to the Company's Chief Executive Officer, Chief Financial Officer, and Executive Chairman. 

          Broker
    For Against Abstentions Non-Votes
    166,325 30,688 1,194 164,374

    Proposal 5: Approval of, for purposes of complying with Nasdaq Listing Rules 5635(c) and 5635(d), the issuance of Common Shares underlying pre-funded warrants and warrants sold in the Company's private placement transactions entered into by the Company with certain investors, pursuant to securities purchase agreements, dated on or about September 19, 2025 (the "September 2025 Private Placement"). 

          Broker
    For Against Abstentions Non-Votes
    53,843 27,150 874 164,374

    Proposal 6: Approval of, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of Common Shares underlying the convertible note issued to DeFi Development Corp in the Company's September 2025 Private Placement. 

          Broker
    For Against Abstentions Non-Votes
    53,843 27,076 897 164,374

    Proposal 7: Approval of, for purposes of complying with Nasdaq Listing Rules 5635(c) and 5635(d), the issuance of Common Shares underlying the convertible note issued to Zero Gravity Labs Inc. in the Company's September 2025 Private Placement 

          Broker
    For Against Abstentions Non-Votes
    54,609 27,033 225 164,374

    Proposal 8: Give the Board the authority, at its discretion, to file Articles of Amendment to the Company's amended and restated Articles of Incorporation to effect a forward share split of the Company's outstanding Common Shares, at a ratio between 2:1 to 10:1, without reducing the authorized number of Common Shares, to be effected, if at all, in the sole discretion of the Board at any time within one year of the date of the Meeting without further approval or authorization of our shareholders. 


    For Against Abstentions
    280,700 70,061 11,820

    Proposal 9: Approval of one or more adjournments or postponements of the Meeting by the Company from time to time to permit further solicitation of proxies, if necessary or appropriate, if sufficient votes are not represented at the Meeting to approve one or more of Proposals Nos. 1-8 at the time of such adjournment or postponement or if otherwise determined by the chairperson of the Meeting to be necessary or appropriate. 

    For Against Abstentions
    280,588 80,155 1,838

    Based on the foregoing votes, Proposals 1, 2, 3, 4, 5, 6, 7, 8 and 9 were approved. No other proposals were submitted for shareholder approval at the Annual Meeting. 

    Item 9.01 Financial Statements and Exhibits.

    Exhibit No. Description


    4.1 2022 Incentive Compensation Plan, as amended on June 6, 2023, August 14, 2024, June 30, 2025 and December 19, 2025
       
    10.1 Form of Stock Option Agreement, dated December 19, 2025
       
    104 Cover Page Interactive Data File


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

      FLORA GROWTH CORP.
         
    Date: December 22, 2025 By: /s/ Dany Vaiman
      Name: Dany Vaiman
      Title: Chief Financial Officer


    Get the next $FLGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLGC

    DatePrice TargetRatingAnalyst
    11/25/2024$4.00Buy
    Aegis Capital
    10/13/2021$10.00Buy
    Roth Capital
    6/23/2021$6.00Buy
    MKM Partners
    More analyst ratings

    $FLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CFO Vaiman Dany

    4 - Flora Growth Corp. (0001790169) (Issuer)

    12/22/25 5:15:05 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Reis-Faria Daniel

    4 - Flora Growth Corp. (0001790169) (Issuer)

    12/22/25 5:13:21 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Chairman Heinrich Michael

    4 - Flora Growth Corp. (0001790169) (Issuer)

    12/22/25 5:02:16 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    SEC Filings

    View All

    SEC Form S-3 filed by Flora Growth Corp.

    S-3 - Flora Growth Corp. (0001790169) (Filer)

    1/8/26 4:02:21 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. filed SEC Form 8-K: Leadership Update

    8-K - Flora Growth Corp. (0001790169) (Filer)

    1/6/26 4:01:36 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Flora Growth Corp. (0001790169) (Filer)

    12/31/25 4:18:03 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Starke Clifford bought $6,455 worth of shares (6,795 units at $0.95), increasing direct ownership by 13,324% to 6,846 units (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/17/24 10:17:39 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wolkin Harold bought $24,255 worth of shares (25,000 units at $0.97) (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/11/24 5:43:51 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Starke Clifford bought $48 worth of shares (51 units at $0.95), increasing direct ownership by 0.01% to 474,046 units (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/6/24 5:25:10 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SRx Health Solutions Appoints Sammy Dorf to Board of Directors

    TAMPA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE:SRXH) (the "Company") today announced the appointment of Sammy Dorf, Esq. to its Board of Directors. Sammy is a pioneering force in the modern cannabis economy and one of the industry's most accomplished dealmakers, strategists, and growth architects. Most recently serving as Executive Chairman of Flora Growth Corp. (NASDAQ:FLGC), Sammy guided the company through a transformative phase marked by innovation, disciplined expansion, and a strategic transition into a crypto treasury company. With nearly a decade of leadership at the intersection of cannabis, capital markets, and strategic development, Sammy b

    11/10/25 8:00:00 AM ET
    $FLGC
    $SRXH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Flora Growth Corp. Announces Second Purchase of 0G, the Fuel of the 0G Decentralized AI Network

    Fort Lauderdale, Florida--(Newsfile Corp. - October 21, 2025) - Flora Growth Corp. (NASDAQ:FLGC) (the "Company"), which is set to rebrand as ZeroStack, and is the first public company to offer exposure to Decentralized AI through the accumulation of $0G, the native cryptocurrency of the distributed AI infrastructure project 0G ("0G"), today announced the purchase of 880,025 $0G at an average price of $2.27. The purchase represents the Company's second acquisition of $0G since its most recent $401 million fundraising and strategic shift to build the world's first publicly listed 0G treasury.Below is a summary of the Company's current $0G position and key per-share metrics as of October 21, 20

    10/21/25 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. Appoints BitGo as Custodian for $0G Treasury

    Fort Lauderdale, Florida--(Newsfile Corp. - October 16, 2025) - Flora Growth Corp. (NASDAQ:FLGC), which is set to rebrand as ZeroStack (the "Company"), the first and largest decentralized AI treasury company, has appointed BitGo Trust Company, Inc. ("BitGo") to provide institutional-grade custody for the Company's $0G treasury.BitGo, the digital asset infrastructure company, has enabled its clients to securely navigate the digital asset space since 2013 by delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. The appointment of BitGo is proof of the Company's focused approach to transparency, security, regulatory compliance and operati

    10/16/25 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital initiated coverage on Flora Growth with a new price target

    Aegis Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $4.00

    11/25/24 8:07:10 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Flora Growth with a new price target

    Roth Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $10.00

    10/13/21 9:00:51 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MKM Partners initiated coverage on Flora Growth with a new price target

    MKM Partners initiated coverage of Flora Growth with a rating of Buy and set a new price target of $6.00

    6/23/21 5:36:01 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Flora Growth Corp.

    SC 13G/A - Flora Growth Corp. (0001790169) (Subject)

    11/14/24 2:24:54 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Financials

    Live finance-specific insights

    View All

    Flora Growth Sets Third Quarter 2022 Conference Call for November 28, 2022, at 4:30 P.M. ET

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, will host its third quarter 2022 earnings call via webcast on Monday, November 28 at 4:30 p.m. ET. During the webcast, Flora management will deliver financial and operational results for the third quarter ended September 30, 2022, and provide updates on Flora's commercial wholesale operations, house of brands and life sciences division strategies. Following the webcast, Flora management will open the call to analysts, media and investors in a Q&A format. Live Webcast Details Date: Monday, November 28, 2022 Time: 4:30 p.m. ET

    11/21/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth to Host Webcast Discussing M&A Activity and International Market Opportunities - Wednesday, October 26, 2022

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that the Company will be hosting an analyst call on Wednesday, October 26, 2022, at 02:00 p.m. EST via webcast to discuss Flora Growth's recent M&A activity and strategic growth opportunities. The conference call and live webcast will invite analysts to pose questions to Flora and Franchise Global Health's leadership teams regarding the recent announcement of the definitive agreement of acquisition between the two companies and the opportunities within the cannabis industry on the global stage. To access this ca

    10/25/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Awarded Best M&A Deal at Benzinga Cannabis Capital Conference

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that the Company received the Best M&A Deal award at Benzinga's 2022 Cannabis Capital Conference in Chicago. "We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers," said Luis Merchan, Chairman and CEO of Flora. Flora completed the acquisition of JustCBD in February 2022, and it immediately offered the Company an established CPG brand with a por

    9/13/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Leadership Updates

    Live Leadership Updates

    View All

    SRx Health Solutions Appoints Sammy Dorf to Board of Directors

    TAMPA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE:SRXH) (the "Company") today announced the appointment of Sammy Dorf, Esq. to its Board of Directors. Sammy is a pioneering force in the modern cannabis economy and one of the industry's most accomplished dealmakers, strategists, and growth architects. Most recently serving as Executive Chairman of Flora Growth Corp. (NASDAQ:FLGC), Sammy guided the company through a transformative phase marked by innovation, disciplined expansion, and a strategic transition into a crypto treasury company. With nearly a decade of leadership at the intersection of cannabis, capital markets, and strategic development, Sammy b

    11/10/25 8:00:00 AM ET
    $FLGC
    $SRXH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Flora Growth Corp. Appoints BitGo as Custodian for $0G Treasury

    Fort Lauderdale, Florida--(Newsfile Corp. - October 16, 2025) - Flora Growth Corp. (NASDAQ:FLGC), which is set to rebrand as ZeroStack (the "Company"), the first and largest decentralized AI treasury company, has appointed BitGo Trust Company, Inc. ("BitGo") to provide institutional-grade custody for the Company's $0G treasury.BitGo, the digital asset infrastructure company, has enabled its clients to securely navigate the digital asset space since 2013 by delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. The appointment of BitGo is proof of the Company's focused approach to transparency, security, regulatory compliance and operati

    10/16/25 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. Appoints Clifford Starke as Chief Executive Officer and Dany Vaiman as Chief Financial Officer; Regains Compliance with NASDAQ Minimum Bid Requirement

    Fort Lauderdale, Florida--(Newsfile Corp. - June 27, 2023) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a consumer-packaged goods leader serving all 50 states with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, announced today that Clifford Starke has been appointed as Chief Executive Officer to lead its global operations and Dany Vaiman has been appointed as Chief Financial Officer. Mr. Starke, who previously served as President of the Company, takes over for Hussein Rakine, who resigned as CEO but will remain on the Company's Board of Directors. Mr. Rakine expressed his confidence in the appointment, stating, "Clifford's

    6/27/23 4:05:00 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care